Skip to main content

Changes to our National Precertification List (NPL)

Effective August 28, 2018, the following new-to-market drugs require precertification:

  • Retacrit® (recombinant human erythropoietin)
  • Fulphila™ (pegfilgrastim-jmdb)


Effective September 1, 2018, the following new-to-market drug requires precertification:


  • Olumiant® (baricitinib)


Effective March 1, 2019, we’ll require precertification for whole exome sequencing.     


We encourage you to submit precertification requests at least two weeks before the scheduled services. To save time, request precertification electronically — it’s fast, secure and simple! Most precertification requests can be submitted electronically through the provider website or by using your Electronic Medical Record (EMR) system portal.


You can find more information about precertification under the General Information section of the NPL.